Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGIXNASDAQ:ENVBNASDAQ:PPBTNASDAQ:TTOO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGIXCancer Genetics$0.19$0.26$2.11▼$17.50$792K2.722.44 million shs19,116 shsENVBEnveric Biosciences$1.17-3.3%$1.28$1.01▼$11.97$2.89M0.68761,224 shs54,015 shsPPBTPurple Biotech$2.70+13.0%$2.50$2.00▼$16.80$3.59M0.57270,882 shs64,028 shsTTOOT2 Biosystems$0.15-7.4%$0.13$0.06▼$6.80$3.39M0.46590,836 shs26,388 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGIXCancer Genetics0.00%0.00%0.00%0.00%0.00%ENVBEnveric Biosciences0.00%-8.59%-9.29%-55.00%-90.00%PPBTPurple Biotech0.00%+12.50%+16.38%-4.26%+269,999,900.00%TTOOT2 Biosystems0.00%-4.15%+4.09%+11.11%-97.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGIXCancer GeneticsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences2.7584 of 5 stars3.54.00.00.02.70.01.3PPBTPurple Biotech1.8069 of 5 stars3.52.00.00.02.60.00.6TTOOT2 BiosystemsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGIXCancer Genetics 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00754.63% UpsidePPBTPurple Biotech 3.00Buy$33.001,122.22% UpsideTTOOT2 Biosystems 2.00Hold$5.003,233.33% UpsideCurrent Analyst Ratings BreakdownLatest CGIX, ENVB, PPBT, and TTOO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025ENVBEnveric BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGIXCancer Genetics$6.33M0.13N/AN/AN/A∞ENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$27.18 per shareN/ATTOOT2 Biosystems$7.68M0.41N/AN/A($6.91) per share-0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGIXCancer GeneticsN/A-$2.07N/A∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%8/11/2025 (Estimated)PPBTPurple Biotech-$19.88M-$2.62N/AN/AN/AN/A-55.86%-44.67%8/15/2025 (Estimated)TTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%6/2/2025 (Estimated)Latest CGIX, ENVB, PPBT, and TTOO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A3/10/2025Q4 2024PPBTPurple Biotech-$0.22-$0.26-$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGIXCancer GeneticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGIXCancer GeneticsN/AN/AN/AENVBEnveric BiosciencesN/A5.175.17PPBTPurple BiotechN/A1.271.27TTOOT2 BiosystemsN/A0.400.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGIXCancer Genetics8.92%ENVBEnveric Biosciences13.82%PPBTPurple Biotech9.64%TTOOT2 Biosystems23.18%Insider OwnershipCompanyInsider OwnershipCGIXCancer Genetics15.00%ENVBEnveric Biosciences1.10%PPBTPurple Biotech2.98%TTOOT2 Biosystems0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGIXCancer GeneticsN/A4.09 millionN/ANot OptionableENVBEnveric Biosciences202.47 million656,000Not OptionablePPBTPurple Biotech201.33 million1.29 millionOptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableCGIX, ENVB, PPBT, and TTOO HeadlinesRecent News About These CompaniesT2 Biosystems (NASDAQ:TTOO) Coverage Initiated at Wall Street ZenMay 23, 2025 | americanbankingnews.comDespite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?March 5, 2025 | 360dx.comT2 Biosystems initiates major layoffs, seeks asset saleFebruary 22, 2025 | uk.investing.comMedical diagnostics firm T2 Biosystems cuts ‘substantially all’ workersFebruary 18, 2025 | bizjournals.comT2 Biosystems to be delisted from NasdaqFebruary 11, 2025 | msn.comT2 Biosystems stock plunges to 52-week low of $0.22January 30, 2025 | msn.comT2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?January 24, 2025 | bovnews.comT2 Biosystems stock plunges to 52-week low of $0.25January 21, 2025 | msn.comT2 Biosystems amends loan terms, extends maturity dateJanuary 18, 2025 | msn.comT2 Biosystems reports preliminary Q4 revenue $2.3MJanuary 7, 2025 | markets.businessinsider.comT2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024January 7, 2025 | markets.businessinsider.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsJanuary 7, 2025 | finance.yahoo.comT2 Biosystems Enhances Governance and Leadership StabilityJanuary 3, 2025 | tipranks.comT2 Biosystems announces sale of four T2Dx Intruments to European distributorDecember 18, 2024 | markets.businessinsider.comT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorDecember 18, 2024 | finance.yahoo.comT2 Biosystems achieves milestone with 250,000th novel sepsis test shippedDecember 17, 2024 | markets.businessinsider.comT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyDecember 17, 2024 | markets.businessinsider.comT2 Biosystems extends multi-year supplier agreement with VizientDecember 16, 2024 | markets.businessinsider.comT2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection ProductsDecember 16, 2024 | quiverquant.comT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.December 16, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGIX, ENVB, PPBT, and TTOO Company DescriptionsCancer Genetics NASDAQ:CGIXVyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.Enveric Biosciences NASDAQ:ENVB$1.17 -0.04 (-3.30%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.85%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Purple Biotech NASDAQ:PPBT$2.70 +0.31 (+12.97%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.60 -0.10 (-3.70%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.T2 Biosystems NASDAQ:TTOO$0.15 -0.01 (-7.41%) As of 05/30/2025 03:56 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
